Blog

Breaking down acronyms with the experts who work with them day in and day out
March 18, 2019
research_development_blog

Scott Jones, Vice President of Scientific Affairs, helps BioBridge Global and its subsidiaries ensure R&D (research and development) develops processes and products that generate business opportunities. He answers the basic question – “What is R&D?”

What is R&D?

The “R” in R&D stands for research, and the “D” stands for development. BBG uses basic and applied research to discover a solution to a problem or create a new product. We perform the appropriate work and processes for the solution or new product. 

Our focus is to take knowledge or technologies from the scientific community and apply them to solve problems or develop new products at BBG. Here at BBG, we perform more development than research, and the form of research we focus on is applied research rather than basic research.

The R&D process involves multiple steps:

March 11, 2019

Tim Blonkvist, architect with Overland Partners, recently visited BioBridge Global and talked with Belinda Flores, Director, Customer Relationship Management in STBTC, about the development of the organization’s art collection.

Overland Partners designed what is now known as the Headquarters Building in 1994.

March 5, 2019
hiv_patient_cured_blog

A patient in England reportedly has been cured of infection with HIV, the virus that causes AIDS, via a stem cell transplant.

The case, which was reported in the journal Nature and made news around the world, is just the second instance in which a patient’s body has been cleared of the virus. The researchers referred to it as long-term remission, but some experts say it is a cure.

The first case of complete clearing of HIV from the body occurred 12 years ago, in much the same way. The most recent patient, who has not been identified, underwent treatment for Hodgkin lymphoma, and in the process received a stem cell transplant in May 2016.

March 4, 2019
FDA_Regen_Medicine_Guidance

Two regenerative medicine guidance documents drafted last year have now been published by the U.S. Food and Drug Administration. The documents clarify new considerations on the development and review of regenerative medicine therapies.

The first guidance deals with the evaluation of devices used with regenerative medicine advanced therapies. The second guidance covers expedited programs for regenerative medicine therapies for serious conditions.

February 25, 2019
fat-cells-stem-cells-blog-image

Researchers from Japan have found a potential way to make platelets from human stem cells derived from fat cells.

Creating platelets in this manner brings a new way to help patients needing platelet transfusions. This breakthrough can help overcome the five day shelf life of platelets, its limited supply and risks of bacterial contamination.

The study was published in the Journal of Blood.

Fat cell derived platelets were obtained within twelve days, with its characteristics and functions similar to platelets.

The method also has potential application in clinical trials.

“Many researchers are currently working to create manufactured platelets, and have succeeded to a degree as evidenced by the article here,” said Dr. Rachel Beddard, Chief Medical Officer at BioBridge Global.

Pages